Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a weekly shot help type 1 diabetes patients lose weight and control blood sugar?

NCT ID NCT06914895

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests tirzepatide, a once-weekly injection, in 905 adults with type 1 diabetes who are also overweight or obese. Participants will receive either tirzepatide or a placebo for about 49 weeks. The study measures changes in blood sugar control (HbA1c) and body weight, aiming to see if tirzepatide can improve both outcomes safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If it works, tirzepatide could help people with type 1 diabetes better manage their blood sugar and lose weight, potentially reducing insulin needs and improving overall health.
What could go wrong
This is a phase 3 trial, but tirzepatide is already approved for type 2 diabetes, not type 1. It may not work as well in type 1 diabetes, and side effects like nausea or low blood sugar are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 905 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have type 1 diabetes and on insulin treatment for at least one year prior to screening * Have an HbA1c value of 7.0% to 10.5% inclusive, at screening * Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening * Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study Exclusion Criteria: * Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. * Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have had chronic or acute pancreatitis * Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 1 diabetes

Contacts and locations

Locations

  • AOU Renato Dulbecco

    Catanzaro, 88100, Italy

  • Abe Clinic

    Ōita, 870-0039, Japan

  • Advanced Clinical Research, LLC

    Bayamón, 00959, Puerto Rico

  • Albany Medical College, Division of Community Endocrinology

    Albany, New York, 12203, United States

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069, United States

  • Arztpraxis Christine Kosch Pirna

    Pirna, 01796, Germany

  • Atlanta Diabetes Associates

    Atlanta, Georgia, 30318, United States

  • Azienda Ospedale - Università Padova

    Padova, 35128, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50134, Italy

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Boeson Research MSO

    Missoula, Montana, 59804, United States

  • CEDOES

    Vitória, 29055450, Brazil

  • CEINV Salud

    Monterrey, 64020, Mexico

  • CENUDIAB

    Buenos Aires, C1440AAD, Argentina

  • CEPIC - Centro Paulista de Investigação Clínica

    São Paulo, 04266-010, Brazil

  • CHU Montpellier Lapeyronie Hospital

    Montpellier, 34295, France

  • CHU Rangueil

    Toulouse, 31059, France

  • CHU Strasbourg-Hautepierre

    Strasbourg, 67098, France

  • CHUAC-Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006, Spain

  • CIPREC

    Buenos Aires, C1119ACN, Argentina

  • CPCLIN

    São Paulo, 01228-200, Brazil

  • CPQuali Pesquisa Clínica

    São Paulo, 01228-000, Brazil

  • Care Access - Lima

    Lima, Ohio, 45805, United States

  • Care Access - Santa Clarita

    Santa Clarita, California, 91321, United States

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, 91106, France

  • Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre

    Caen, 14033, France

  • Centre Hospitalier intercommunal de Toulon La Seyne sur Mer

    Toulon, 83100, France

  • Centre du diabète DIAB-eCARE

    Lyon, 69008, France

  • Centro De Diabetes Metabolismo E Endocrinologia

    Fortaleza, 60175-047, Brazil

  • Centro Medico Privado San Vicente Diabetes

    Córdoba, 5006, Argentina

  • Centro de Diabetes Curitiba

    Curitiba, 80810-040, Brazil

  • Centro de Diagnóstico y Rehabilitación (CEDIR)

    Santa Fe, 3000, Argentina

  • Centro de Investigacion Medica de Occidente, S.C.

    Guadalajara, 44260, Mexico

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, C1056ABI, Argentina

  • Centro de Investigaciones Médicas Mar del Plata

    Mar del Plata, 7600, Argentina

  • Centro de Salud e Investigaciones Médicas

    Santa Rosa, L6300, Argentina

  • Clinic Masae Minami

    Fukuoka, 815-0071, Japan

  • Clínica García Flores SC

    Monterrey, 64610, Mexico

  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval

    Ferrol, 15405, Spain

  • Consultorio Médico de Endocrinología y Pediatría

    Puebla City, 72190, Mexico

  • Consultorio de Investigación Clínica EMO SRL

    Buenos Aires, C1405BUB, Argentina

  • Diabetes Medical Center

    Tel Aviv, 51549, Israel

  • Diabetes Zentrum Wilhelmsburg

    Hamburg, 21109, Germany

  • Diabetes- und Stoffwechselpraxis Bochum

    Bochum, 44869, Germany

  • Diabetespraxis Mergentheim

    Bad Mergentheim, 97980, Germany

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • Eastside Research Associates

    Redmond, Washington, 98052, United States

  • Enclifar Ensayos Clínicos Farmacológicos Sc

    Chihuahua City, 31110, Mexico

  • Endocrine and Metabolic Consultants

    Rockville, Maryland, 20852, United States

  • Esbjerg sygehus, Syddansk Universitetshospital

    Esbjerg, 6700, Denmark

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

    Roma, 00168, Italy

  • Fundacion Estudios Clinicos

    Rosario, 2000, Argentina

  • Groupe Hospitalier Mutualiste Les Portes du Sud

    Vénissieux, 69200, France

  • Hachioji Diabetes Clinic

    Hachioji-shi, 192-0083, Japan

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • HealthPartners Institute dba International Diabetes Center

    Minneapolis, Minnesota, 55416, United States

  • Heiwadai Hospital

    Miyazaki, 880-0034, Japan

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41013, Spain

  • Hospital Universitario de Móstoles

    Móstoles, 28935, Spain

  • Hospital das Clinicas FMUSP

    São Paulo, 05403-000, Brazil

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • Hôpital Européen Marseille

    Marseille, 13003, France

  • Hôpital NOVO

    Pontoise, 95300, France

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

    Nantes, 44093, France

  • Hôpital de la Conception

    Marseille, 13005, France

  • Hôtel-Dieu du Creusot - site Harfleur

    Le Creusot, 71200, France

  • IBTED - Tecnologia e Educação em Diabetes

    São Paulo, 04038-032, Brazil

  • IRCCS - AOU di Bologna

    Bologna, 40138, Italy

  • Indiana University Health University Hospital

    Indianapolis, Indiana, 46202, United States

  • InnoDiab Forschung Gmbh

    Essen, 45136, Germany

  • Institut für Diabetesforschung GmbH Münster

    Münster, 48145, Germany

  • Institute of Diabetes, Technology and Research - Clalit Health

    Herzliya, 4600201, Israel

  • Instituto Médico Río Cuarto

    Río Cuarto, X5800AEV, Argentina

  • Instituto de Investigaciones Clínicas Córdoba

    Córdoba, 5000, Argentina

  • Invecordis S.C.

    Hacienda de Las Palmas, 52763, Mexico

  • Investigaciones Medicas Imoba Srl

    Buenos Aires, C1056ABH, Argentina

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50266, United States

  • Japanese Red Cross Fukuoka Hospital

    Fukuoka, 815-8555, Japan

  • Japanese Red Cross Society - Wakayama Medical Center

    Wakayama, 640-8558, Japan

  • Jinnouchi Hospital

    Kumamoto, 862-0976, Japan

  • Kasugai Municipal Hospital

    Kasugai, 486-8510, Japan

  • Kimitsu Chuo Hospital

    Kisarazu, 292-8535, Japan

  • Klinikum Karlsburg

    Karlsburg, 17495, Germany

  • Kozawa Eye Hospital and Diabetes Center

    Mito, 310-0845, Japan

  • Kumamoto Central Hospital - Kumamoto

    Kumamoto, 862-0965, Japan

  • Kure Medical Center

    Kure, 737-0023, Japan

  • Lucas Research, Inc.

    Morehead City, North Carolina, 28557, United States

  • Manati Center for Clinical Research

    Manati, 00674, Puerto Rico

  • Manda Memorial Hospital

    Sapporo, 060-0062, Japan

  • Matoba Internal Medicine Clinic

    Ebina, 243-0432, Japan

  • Medrasa Clinical Research

    Wylie, Texas, 75098, United States

  • Medsal Centro Médico

    Tampico, 89210, Mexico

  • Mikannohana Clinic, Diabetes, Endocrinology and Metabolism

    Matsuyama, 790-0034, Japan

  • NYC Research

    New York, New York, 10016, United States

  • Nakakinen clinic

    Naka, 311-0113, Japan

  • Nordsjællands Hospital - Hillerød

    Hillerød, 3400, Denmark

  • Noritake Clinic

    Ushiku, 300-1207, Japan

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189, United States

  • Odori Diabetes

    Sapporo, 060-0001, Japan

  • Orita Clinical Research

    Decatur, Georgia, 30034, United States

  • Osaka City General Hospital

    Osaka, 534-0021, Japan

  • Ospedale San Raffaele

    Milan, 20132, Italy

  • Palm Research Center Sunset

    Las Vegas, Nevada, 89148, United States

  • Palm Research Center Tenaya

    Las Vegas, Nevada, 89128, United States

  • Private Practice - Dr.Miguel N. Hissa

    Fortaleza, 60430-350, Brazil

  • RED-Institut GmbH

    Oldenburg, 23758, Germany

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rainier Clinical Research Center

    Renton, Washington, 98057, United States

  • Rambam Health Care Campus

    Haifa, 3109601, Israel

  • Regionshospitalet Gødstrup

    Herning, 7400, Denmark

  • Research Foundation of SUNY - University of Buffalo

    Buffalo, New York, 14221, United States

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho, 83404, United States

  • SKY Integrative Medical Center/SKYCRNG

    Ridgeland, Mississippi, 39157, United States

  • SUNY Upstate Medical University

    Syracuse, New York, 13210, United States

  • Sansum Diabetes Research Institute

    Santa Barbara, California, 93105, United States

  • Schneider Children's Medical Center

    Petah Tikva, 4920235, Israel

  • Sheba Medical Center

    Ramat Gan, 5262100, Israel

  • Shimonoseki Medical Center

    Shimonoseki, 750-0061, Japan

  • Shiraiwa Medical Clinic

    Kashiwara, 582-0005, Japan

  • Sjællands Universitetshospital Køge

    Køge, 4600, Denmark

  • Soleil Chikusa Clinic

    Nagoya, 464-0858, Japan

  • Soroka Medical Center

    Beersheba, 8410101, Israel

  • Sourasky Medical Center

    Tel Aviv, 6423906, Israel

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Steno Diabetes Center - Copenhagen

    Herlev, 2730, Denmark

  • Suburban Research Associates

    West Chester, Pennsylvania, 19380, United States

  • Suruga Clinic

    Shizuoka, 424-0855, Japan

  • Takai Internal Medicine Clinic

    Kamakura-shi, 247-0056, Japan

  • Tama Center Clinic Mirai

    Tama, 206-0033, Japan

  • Tekton Research, LLC.

    McKinney, Texas, 75069, United States

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas, 78731, United States

  • The Institute of Medical Science, Asahi Life Foundation

    Chūōku, 103-0002, Japan

  • Tomonaga Clinic

    Shinjuku, 160-0022, Japan

  • Tosaki Clinic for Diabetes and Endocrinology

    Nagoya, 468-0009, Japan

  • Unidad de Investigación Clínica y Atención Médica HEPA S.C.

    Guadalajara, 44670, Mexico

  • Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente

    Guadalajara, 44150, Mexico

  • Universidade Federal de Goias

    Goiânia, 74605-020, Brazil

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Naples Federico II

    Naples, 80100, Italy

  • Universitätsklinikum Leipzig

    Leipzig, 04103, Germany

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Yamanashi Prefectural Central Hospital

    Kofu, 400-8506, Japan

  • Yitzhak Shamir Medical Center

    Beer Yaacov, 70300, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.